국가: 오스트레일리아
언어: 영어
출처: Department of Health (Therapeutic Goods Administration)
carmustine, Quantity: 100 mg
Dr Reddys Laboratories Australia Pty Ltd
Injection, diluent for
Excipient Ingredients: ethanol absolute
Intravenous Infusion
1 powder for injection vial and 1 diluent vial
(S4) Prescription Only Medicine
CARMUSTINE DR.REDDY'S is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. Malignant Glioma 2. Multiple Myeloma - in combination with prednisone. 3. Hodgkin?s Disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. Non-Hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Visual Identification: Clear, colourless, mobile, volatile liquid; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2020-08-12